Tremfya (guselkumab) vs Bimzelx (bimekizumab-bkzx)
Tremfya (guselkumab) vs Bimzelx (bimekizumab-bkzx)
Tremfya (guselkumab) is a human monoclonal antibody that selectively blocks the protein interleukin-23 (IL-23), which is known to play a key role in the pathogenesis of plaque psoriasis. Bimzelx (bimekizumab-bkzx), on the other hand, is a humanized monoclonal IgG1 antibody that inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key pro-inflammatory cytokines involved in inflammatory processes, including those seen in psoriasis. When deciding between the two, a patient should consider factors such as the specific cytokine targets of each medication, their individual medical history, potential side effects, and the advice of their healthcare provider, as both medications are used for moderate to severe plaque psoriasis but may have different efficacy and safety profiles for each individual.
Difference between Tremfya and Bimzelx
Metric | Tremfya (guselkumab) | Bimzelx (bimekizumab-bkzx) |
---|---|---|
Generic name | Guselkumab | Bimekizumab-bkzx |
Indications | Plaque psoriasis, psoriatic arthritis | Plaque psoriasis |
Mechanism of action | IL-23 inhibitor | IL-17A and IL-17F inhibitor |
Brand names | Tremfya | Bimzelx |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Upper respiratory infections, headache, injection site reactions | Upper respiratory tract infection, oral candidiasis, injection site reactions |
Contraindications | Active tuberculosis, severe infections | Active tuberculosis, severe infections |
Drug class | Monoclonal antibody | Monoclonal antibody |
Manufacturer | Janssen Biotech | UCB, Inc. |
Efficacy
Efficacy of Tremfya (Guselkumab) for Psoriasis
Tremfya (guselkumab) is a biologic medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Guselkumab is an interleukin-23 (IL-23) inhibitor that targets a specific protein involved in the inflammatory process of psoriasis, leading to the reduction of the signs and symptoms of the condition. Clinical trials have demonstrated the efficacy of Tremfya in achieving clear or almost clear skin. The majority of patients treated with Tremfya experienced significant improvement in their psoriasis symptoms, as measured by the Psoriasis Area and Severity Index (PASI) score.
In pivotal phase III clinical trials, such as VOYAGE 1 and VOYAGE 2, a significant proportion of patients achieved PASI 90 and PASI 100 responses, indicating a 90% and 100% reduction in PASI score, respectively. These outcomes were maintained through 48 weeks of treatment. Furthermore, patients reported improvements in quality of life and other patient-reported outcomes, highlighting the beneficial impact of Tremfya on daily living and overall well-being.
Efficacy of Bimzelx (Bimekizumab-bkzx) for Psoriasis
Bimzelx (bimekizumab-bkzx) is a newer biologic therapy that has been approved for the treatment of moderate-to-severe plaque psoriasis in adults. Bimekizumab is a monoclonal antibody that selectively inhibits both interleukin-17A (IL-17A) and interleukin-17F (IL-17F), two key cytokines involved in the inflammatory processes associated with psoriasis. Clinical studies have shown that Bimzelx can lead to significant skin clearance in individuals with psoriasis, with many patients achieving PASI 90 and PASI 100 responses, indicating substantial or complete clearance of psoriatic lesions.
In the BE VIVID, BE READY, and BE SURE phase III clinical trials, bimekizumab demonstrated rapid and sustained efficacy in improving psoriasis symptoms. A high percentage of patients achieved PASI 90 and PASI 100 responses at week 16, which were maintained through to week 52 in many cases. Additionally, patients treated with Bimzelx reported enhanced quality of life and symptom relief, which supports its efficacy in managing the physical and psychological burden of psoriasis.
Regulatory Agency Approvals
Tremfya
Bimzelx
Access Tremfya or Bimzelx today
If Tremfya or Bimzelx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us